New combo of immunotherapy drugs is safe, shrinks tumors in metastatic melanoma patients

(University of Pennsylvania School of Medicine) Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.